

3rd February 2025

- | | |
|---|---|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Investment in Cipla Medpro South Africa Proprietary Limited, wholly owned subsidiary

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby notify that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the Company in South Africa (“CMSA”).

Details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 on the captioned subject are enclosed to this letter.

We request you to kindly take the above disclosure on record.

Thanking you,
Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Akshaya Kolvankar

Annexure – I

Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover, etc.	<p>Cipla Medpro South Africa Proprietary Limited (“CMSA”)</p> <p>CMSA, is a wholly owned subsidiary of Cipla Limited, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical products.</p> <p>Turnover as on 31st March 2024: ZAR 688.28 million</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>The transaction is a related party transaction and will be at arm’s length.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p>
c)	Industry to which the entity being acquired belongs	Pharmaceutical
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment will be utilised to reduce inter-group debt and improve the capital structure of CMSA and its subsidiaries.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable.
f)	Indicative time-period for completion of the acquisition	The investment is expected to be completed on or before 28 th February 2025 or such other date mutually agreed between the parties.
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration.

h)	Cost of acquisition and/or the price at which the shares are acquired	Cost of acquisition: ZAR 899,999,992								
i)	Percentage of shareholding / control acquired and / or number of shares acquired	Number of equity shares: 40,742,417								
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief background: Refer (a) above.</p> <p>Date of Incorporation: 15th July 2013</p> <p>History of last 3 years turnover:</p> <table border="1" data-bbox="786 600 1219 770"> <thead> <tr> <th data-bbox="786 600 963 642">FY</th> <th data-bbox="963 600 1219 642">Turnover</th> </tr> </thead> <tbody> <tr> <td data-bbox="786 642 963 684">FY 2023-24</td> <td data-bbox="963 642 1219 684">ZAR 688.28 million</td> </tr> <tr> <td data-bbox="786 684 963 726">FY 2022-23</td> <td data-bbox="963 684 1219 726">ZAR 1.12 billion</td> </tr> <tr> <td data-bbox="786 726 963 770">FY 2021-22</td> <td data-bbox="963 726 1219 770">ZAR 1.71 billion</td> </tr> </tbody> </table> <p>Country in which CMSA has its presence: South Africa</p>	FY	Turnover	FY 2023-24	ZAR 688.28 million	FY 2022-23	ZAR 1.12 billion	FY 2021-22	ZAR 1.71 billion
FY	Turnover									
FY 2023-24	ZAR 688.28 million									
FY 2022-23	ZAR 1.12 billion									
FY 2021-22	ZAR 1.71 billion									